Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.05 CAD | +11.11% | -23.08% | -54.55% |
02:49pm | Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD | CI |
05-31 | Transcript : Numinus Wellness Inc. - Shareholder/Analyst Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.55% | 10.54M | |
+50.44% | 59.28B | |
+41.42% | 40.94B | |
-5.42% | 40.17B | |
-5.16% | 28.69B | |
+12.90% | 26.63B | |
-20.42% | 18.89B | |
+31.20% | 12.46B | |
+0.40% | 12.42B | |
+26.17% | 12.26B |
- Stock Market
- Equities
- NUMI Stock
- News Numinus Wellness Inc.
- Numinus Wellness Brief: Q1 FY24 Revs of $5.9 million, a 3.0% decline over Q4 2023; Loss and Comprehensive Loss $4,351,472